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Tumor Recognition following V9V2 T Cell
Receptor Interactions with a Surface
F1-ATPase-Related Structure and Apolipoprotein A-I
I or class II major histocompatibility complex (MHC)mol-
ecules. Besides these “conventional” T cells, other sub-
sets expressing either  or  TCR react against amore
heterogeneous set of nonpeptidic compounds, either in
a native form or in association with conserved MHC-
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lymphoma growth upon human V9V2 T cell transfer
into severe combined immunodeficientmice (Malkovska
et al., 1994), and the implication of murine  T cells inSummary
early control of chemically inducedcutaneousmalignan-
cies (Girardi et al., 2001, 2003).V9V2 T lymphocytes, a major  T lymphocyte sub-
Some human  T cells of the V1 subset react towardset in humans, display cytolytic activity against various
the nonclassicalMHCmoleculesMICA andMICB, whichtumor cells upon recognition of yet uncharacterized
are stress induced. It is not clear, however, if this recog-structures. Here, we show that an entity related to the
nition is mediated by TCR (Groh et al., 1998) or bymitochondrial F1-ATPase is expressed on tumor cell
NKG2Dmolecules (Wuet al., 2002). In the caseof V9V2surface and promotes tumor recognition by V9V2
T cells, the tumor antigens targeted by the TCR remainTcells.When immobilized, purifiedF1-ATPase induces
unknown so far. Recognition of tumor cells, such asselective activation of this lymphocyte subset. The
the Daudi lymphoma by V9V2 T cells, correlates withV9V2 T cell receptors (TCR) and the F1-ATPase also
production of mevalonate metabolites such as isopen-bind a delipidated form of apolipoprotein A-I (apo A-I),
tenyl pyrophosphate (IPP) (Gober et al., 2003). This phe-as demonstrated by surface plasmon resonance.
nomenon could account for the dual recognition of solu-Moreover, the presence of apo A-I in the culture me-
ble nonpeptidic and tumor antigens by the same T celldium is required for optimal activation of V9V2
population. However, efficient activation of V9V2T cells by tumors expressing F1-ATPase. This study
T cells requires millimolar concentrations of IPP, a con-thus describes an unanticipated tumor recognition
centration range that is unlikely to be reached in themechanism by V9V2 lymphocytes and a possible
extracellular medium in physiological conditions. Thus,link between  T cell immunity and lipid metabolism.
tumor cell recognition probably also involves stable cell
surface components. In this work, we show that a sur-Introduction
face structure related to the mitochondrial F1-ATPase
Through their  TCR, peripheral T lymphocytes classi- (F1) is present on the surface of V9V2-susceptible
cally recognize foreign peptidic antigens bound to class tumors, selectively binds to the V9V2 TCR, and is
implicated in tumor recognition by V9V2 cells. This
unexpected mechanism of tumor recognition is also*Correspondence: eric.champagne@toulouse.inserm.fr (E.C.);
bonnevil@nantes.inserm.fr (M.B.); modulated by ligands for F1 such as apo A-I.
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Figure 1. Extracellular Apo A-I Binds to Tumor Cells
(A) Indirect immunofluorescence staining with M5 mAb or a control IgG1 antibody (shaded histograms) of human cell lines cultured in presence
of fetal calf serum (FCS). Daudi and Raji are Burkitt’s lymphomas cell lines; Awells is a B-lymphoblastoid cell line; K562 is an erythroid leukemia
cell line; RPMI 8226 is a B-cell myeloma cell line; and U937 is a monocytic leukemia cell line. MOLT-4 and Jurkat are T cell leukemia cell lines.
(B) Daudi cells were depleted of serum components by overnight culture in SFM and subsequently incubated in PBS supplemented with
either 10% FCS (SFM/FCS), 10% human serum (SFM/HS), or 1% BSA plus 100 g/ml of M5L (SFM/M5L) before staining as in (A).
(C) Left, Coomassie blue staining of M5-immunopurified material from FCS (lane 1) and HS (lane 2) after nonreducing SDS-polyacrylamide
gel electrophoresis (PAGE). Right, immunoblot after reducing PAGE with antihuman apo A-I antibody 4H1 on HS (lane 3), FCS (lane 4), HDL
(lane 5), and hM5L (human serum ligand of M5 mAb, lane 6).
Results 26 kDawas immunoprecipitatedbyM5mAb, andmass
spectrometry analysis of tryptic peptide digests identi-
fied apo A-I as the likely ligand. M5mAb immunopurifiedModulation of V9V2-Mediated Tumor Cell
Recognition by Apo A-I and Apo A-I-Specific mAb a similar protein from human serum (hM5L), and its iden-
tity to apo A-I was confirmed by its reactivity in immu-In an attempt to characterize surface tumor antigens
involved in the activation of V9V2 T cells, we raised noblotting experiments with the antihuman apo A-I
monoclonal antibody 4H1 (Figure 1C). Accordingly, likemurine monoclonal antibodies (mAb) against the Bur-
kitt’s lymphoma Daudi, a cell line that is lysed by a large M5 mAb, 4H1 stained Daudi, but not Raji cells, after
incubationwith a human lipid-free formof humanapoA-Imajority of V9V2 T cell clones (Davodeau et al., 1993;
De Libero et al., 1991). mAbwere selected for their ability prepared from high-density lipoprotein particles (HDL-
apo A-I) by ion exchange chromatography (data notto differentially bind to Daudi and Raji (a nonactivating
Burkitt’s lymphoma) and to inhibit recognition of Daudi shown).
M5 decreased in vitro lysis of Daudi cells mediatedcells by V9V2 T cells. OnemAb (#M5A12D10, hereafter
referred to asM5) that fulfilled both criteria was selected by V9V2 T cell clones or a polyclonal V9V2 T cell
line. By contrast, Daudi cell lysis by a reactive V8V3for further studies. M5 mAb stained several cell lines
killed in vitro by V9V2 T cells, such as Daudi and K562, T cell clone (#73R9)wasnot affectedbyM5mAb (Figures
2A and 2B). In order to assess the putative involvementbut did not stain several V9V2-resistant tumors, such
as Raji lymphoma and Awells B lymphoblastoid cells of apo A-I in V9V2 cytolytic activity, cytotoxicity
assays were performed in SFM by using target cells(Figure 1A). As M5mAb binding to tumor cells was dras-
tically decreasedwhen cells were cultured in serum-free depleted of serum after an overnight culture in SFM
(Figure 2B). The cytolytic activity of V9V2 T cell clonesmedium (SFM) (Figure 1B), this mAb was subsequently
used to immunopurify a putative ligand from bovine se- against Daudi cells was decreased in serum-free condi-
tions and restored by addition of serum during the cyto-rum. A protein (M5L) of apparent molecular weight of
Tumor Recognition by V9V2 Lymphocytes
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Figure 2. Apo A-I Modulates Tumor Lysis
TubL is a polyclonal V9V2 line; G25, G115,
G42, and 73R9 are T cell clones expressing
the indicated TCR.
(A) Standard 51Cr-release assay onDaudi cells
with, as effectors, T cell clones and lines
bearing the indicated TCR variable regions.
The assay was performed in medium con-
taining 10% FCS (effector:target ratio, 10:1)
and variable concentrations of M5 mAb
(closed circles) or of a control IgG1 mAb
(open circles). Specific lysis of Daudi cells
for G42, G115, TubL, and 73R9 was 56.7%,
61.3%, 52.9%, and 63.5% respectively.
(B) Effector T cells (top) and target cell lines
(horizontal axis) were serumdepleted and co-
cultured for 2 hr in SFM (white bars) at an
effector:target ratio of 10:1. Black bars indi-
cate the increase of lysis efficiency in wells
supplemented with 3% FCS.
(C) 51Cr-release assays were performed in
SFM to assess dependence on serum and
apoA-I of Daudi cytolysis by different effector
T cell populations. M5L (bovine serum com-
ponent immunopurified with M5 antibody),
and apo A-I preparations were added at the
100 g/ml or at the indicated concentration
to assess their ability to substitute for serum
(FCS). Recombinant Annexin V was used as
a control purified protein.
toxicity assay. Similarly, addition of purified M5L in- not shown), we studied expression of a high-affinity apo
A-I receptor recently identified on hepatocytes, namelycreased V9V2 T cell-mediated lysis in a dose-
dependent manner. By contrast, Daudi cell lysis by the the ATP synthase/F1-ATPase complex (Martinez et al.,
2003). Subunits of this complex were clearly detectedcontrol V8V3 T cell clone was neither affected by se-
rum deprivation nor by addition of M5L (Figures 2A and on several tumor cell lines (Figure 3). In particular, Daudi,
K562, and RPMI 8226 were stained by mAb against2B). A similar effect on V9V2 T cell cytotoxicity was
observed by using HDL-apo A-I or a commercial apo the  chain of F1-ATPase (F1), whereas Raji, leukemic
T cells, and B-LCL were not (Figure 3A). Four kidneyA-I preparation, thus ruling out a nonspecific stimulatory
effect (Figure 2C). tumors that were lysed by V9V2 CTL (E.S. and M.B.,
unpublished data) also expressed an F1-related sur-The effect of apo A-I on Daudi cell lysis significantly
varied from one V9V2 T cell clone to another, with face component (Figure 3C). The  subunit of F1 (F1)
some clones, like #G25, being highly dependent on apo was detected on Daudi, K562, and U937, a monocytic
A-I, whereas other ones, like #G115, were less affected. line not consistently killed by V9V2 T cells. This chain
This clonal variability may involve TCR-dependent and was undetectable onRPMI 8226 and kidney tumors (Fig-
TCR-independent mechanisms. Irrespective of this is- ures 3B and 3C). Therefore, tumor susceptibility to
sue, the fact that cytotoxicity of V9V2 clones, unlike V9V2 lysis strongly correlates with expression of the
that of other  or  clones, was in most instances F1 subunit. Moreover, M5 staining correlates with the
sensitive to apo A-I suggested specific contribution of detection of F1, in agreement with binding of apo A-I
apo A-I in V9V2-mediated recognition of tumor cells. to theF1 subunit on hepatocytes (Martinez et al., 2003).
To further evaluate the possible involvement of F1 in
tumor cell recognition by V9V2 T cells, we investigatedImplication of F1, an Apo A-I Receptor, in Tumor
the effect of F1-specific mAb on lymphokine productionCell Recognition by V9V2 T Cells
induced upon short-term incubation of V9V2 T cellAlthough apo A-I modulated tumor cell recognition by
clones with Daudi cells. IFN secretion was stronglyV9V2 cells, it could not be the only factor controlling
inhibited by anti-F1, anti-F1, and M5 antibodies whentumor susceptibility to V9V2 cell recognition owing to
compared to control mAb. This inhibition was not dueits ubiquitous and soluble nature. We therefore under-
to a nonspecific toxic effect, as indicated by the lack oftook a detailed analysis of apo A-I receptors on several
inhibition of IPP-induced V9V2 T cell activation by M5tumor cell lines. Scatchard analysis of the binding of
or anti-F1 mAb (Figure 4).iodinated apo A-I to Daudi cells indicated the presence
To confirm the implication of F1 in V9V2 T cell acti-of a single binding receptor on these cells (KD  0.8 
vation, latex beads were coated with purified bovine107 M) (Supplemental Figure S1 available online at
mitochondrial F1 complex and/or apo A-I and testedhttp://www.immunity/com/cgi/content/full/22/1/71/
for their ability to stimulate V9V2 and control T cellDC1). Because Daudi cells do not express the long-
populations (Figure 5). Coculturewith beads coatedwithknownapoA-I receptors ScavengerReceptorB1 (Murao
et al., 1997) or ABCA-1 (Chambenoit et al., 2001) (data bovine F1 induced strong TNF secretion by V9V2
Immunity
74
Figure 3. Expression of F1-Related Structures on Tumor Cells
(A and B) Indirect immunofluorescence surface staining of hematopoietic tumor lines with (A) anti-F1 and (B) anti-F1 mAb.
(C) Four kidney tumors sensitive to V9V2 lysis were tested for expression of F1 by FACS staining by using control IgG (shaded histogram),
anti-F1 (dark line), and anti-F1 mAb (dotted line).
clones, whereas V8V3 and  clones, otherwise able Cognate Interactions between V9V2 TCR,
F1, and Apo A-Ito produce TNF after stimulation by phorbol myristate
acetate and calcium ionophore, were not activated (Fig- To further document the implication of the TCR in F1-
and apo A-I-mediated activation of V9V2 T cells, weure 5A). Immobilized apo A-I alone failed to stimulate
V9V2 T cell clones. Similar experiments performed in studied interactions between purified F1, apolipopro-
teins, and soluble recombinant forms of  TCRs inserum-free conditions showed a stimulatory activity of
beads carrying F1 alone and a relatively minor increase acellular systems. When tetramerized by fluorescent
streptavidin, the V9V2 TCR derived from the G115of this stimulatory activity after addition of soluble apo
A-I (Figure 5B). This would suggest an accessory role clone (Allison et al., 2001) stainedDaudi, K562, andmore
weakly RPMI 8226, but neitherRaji nor B lymphoblastoidplayed by apoA-I in F1-induced V9V2 T cell activation.
However, carryover of apo A-I or related apolipoproteins cell lines. V8V3 TCR derived from clone 73R9 stained
Daudi and, to a much lesser extent, K562 cells (Supple-by effector cells could not be formally ruled out in such
experiments. Consistent with a highly restricted stimula- mental Figure S1 and data not shown). This strongly
suggests that the two different TCR target different li-tory activity of F1 on the V9V2 T cell subset, beads
carrying F1 and apo A-I induced selective TNF produc- gands on Daudi cells, in agreement with the distinct
lysis patterns of the original T cell clones (see Figure 2).tion by a large fraction of V2	 T cells when added onto
fresh peripheral blood lymphocytes (PBL) but had no Interaction of monomeric soluble TCR with apo A-I and
F1was then tested by surface plasmon resonance (SPR)significant effect on  and NK cell populations (Fig-
ure 5C). analysis (Figure 6). In these conditions, soluble G115
Tumor Recognition by V9V2 Lymphocytes
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(Crowley et al., 2000) and several CD1d-restricted NKT
cell clones (Brossay et al., 1998; Stanic et al., 2003). In
particular, binding affinity of V9V2 TCR for F1 and
apo A-I are in the 106–107 M range and thus can be
considered as high-affinity interactions when compared
to the binding affinities of TCR for peptide/MHCcom-
plexes (classically in the 104–106 M range [Davis et
al., 1998]). As for murine  T cells, high binding affinity
of V9V2 TCR for its presently described ligands is
mainly accounted for by a very fast association rate and
a rather slow dissociation rate. As previously suggested
(Crowley et al., 2000), these features may allow V9V2
TCR to efficiently catch transient/unstable complexesFigure 4. Modulation of Lymphokine Secretion by Anti-F1 Anti-
formed between F1, apoA-I, and possibly other tumorbodies
ligands (such as phosphoantigens, see below). Besides,Left, Daudi cells were incubated in serum, washed, and incubated
these results are consistent with the immunoglobulin-with serum-depleted V9V2 cells (clone G42) in SFM, in the pres-
ence of the indicated concentration of antibodies, and the produc- like features of V9V2 TCR suggested by a recent crys-
tion of -interferon was measured after a 20 hr coculture. Right, tallographic study (Allison et al., 2001).
to exclude a possible toxicity of antibodies on responding cells, Although unexpected, the ectopic detection of F1 on
antibodies were dialyzed, and isopentenyl pyrophosphate (IPP, 2 the cell surface is not unprecedented as it has already
g/ml) was added in some cultures.
been described onK562 cells (Das et al., 1994), endothe-
lial cells (Moser et al., 1999), and hepatocytes (Martinez
et al., 2003). Furthermore, the presence of F1 within lipidTCR, unlike 73R9 TCR, specifically bound to apo A-I
rafts on HeLa cells has been recently reported (Bae etimmobilized onto SPR chips (KD  0.8 M). V9V2 also
al., 2004). Different functions have been attributed tobound to SPR chips coated with soluble bovine F1 com-
this structure, including an immunoregulatory role in theplex (KD  1.5 M), unlike control V8V3 TCR. These
case of tumors (Das et al., 1994), angiostatin receptorresults demonstrated the occurrence of specific interac-
(Moser et al., 1999), and regulation of lipoprotein trans-tions between the V9V2 TCR, apoA-I, and F1, possibly
port through high-affinity apo A-I binding (Martinez etthrough formation of a trimolecular complex. In order
al., 2003). The structure found on Daudi and K562 cellsto analyze further the respective contribution of apo A-I
is not a crossreactive entity unrelated to F1 becauseand F1, another experimental setting was used. Purified
bovine F1 complex,when immobilized on plastic or latexATP synthase was immobilized onto plastic wells and
beads, also binds soluble V9V2 TCR and activatesbinding of soluble biotinylated recombinant TCR was
specifically V9V2 cells.quantitated by a streptavidin-alkaline phosphatase col-
Available monoclonal antibodies reveal a striking dis-orimetric assay. Soluble V9V2 TCR bound to ATP syn-
sociation between the expression of the F1 and F1
thase-coated wells and addition of hM5L onto immobi-
subunits on tumor cell lines, suggesting some form of
lized ATP synthase increased subsequent TCR binding
polymorphism of this structure. Although the mitochon-
by 30%–40% under these conditions (Figures 7A and
drial receptor has similar stimulatory properties for 
7B). This bindingwascompeted by anti-clonotypicmAb, cells, the structure displayed on the plasma membrane
but not by irrelevant V- or V-specific mAb (Figure 7C). may use some of its components to perform different
TCRbindingwas inhibited in a specific anddose-depen- functions. The isolated expression of F1 or F1 sub-
dent manner by anti-F1 or anti-F1 antibodies (Figures units on the cell surface seems unlikely, as these sub-
7A and 7B). Finally, hM5L increased TCR binding even units do not contain any membrane anchor domains.
in the presence of anti-F1 antibodies, suggesting that Thus, we would favor the possibility that on some cells
these antibodies do not impede the bridging of TCR and the F1 or the F1 chains are either hindered or replaced
F1 by hM5L. Moreover, the anti-apo A-I antibody 4H1 by yet unknown structures. A predominant role of F1
did not prevent TCR binding to F1 but inhibited the as a V9V2 TCR target is suggested by the correlation
binding increment provided by hM5L (Figure 7B). These between tumor sensitivity to V9V2 cytotoxicity and
results suggest that apo A-I acts as a stabilizer of the surface expression of F1. Nevertheless, its implication
TCR-F1 interaction. in a protein complex is supported by the inhibitory effect
of anti-F1 antibodies on TCR binding and cytokine
Discussion production. Whether these components are also in-
volved in an enzymatic complex on tumor cells is not
In thiswork,we have identified two ligandsof the V9V2 known yet.
TCR on tumor targets. The first one is immunologically Antibodies to apo A-I moderately affect target lysis
related to the ATP synthase/F1-ATPase normally ex- by V9V2 effectors. Similarly, coimmobilization of apo
pressed on the internal membrane of mitochondria and A-I with F1 has a moderate effect on T cell stimulation
is detected with anti-F1 and/or anti-F1 antibodies. and TCR binding. Immobilization of apo A-I by itself is
The second one corresponds to apo A-I, a recently de- not sufficient to promote stable binding of biotinylated
scribed ligand for F1. The binding parameters of the TCR (data not shown) or to activate V9V2 clones (Fig-
interactions between V9V2 TCR and both ligands are ure 5). This suggests a secondary role of apo A-I. None-
very similar to those reported for several other noncon- theless, addition of serum is required for optimal cyto-
lytic activity of V9V2 T lymphocytes, and this effectventional TCR such as the murine  T cell clone G8
Immunity
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Figure 5. Induction of V9V2 T Cell Lymphokine Secretion by Immobilized F1
HDL-derived apo A-I and F1 were immobilized on latex beads, and these were used to stimulate T cell populations. Legend: none, no
stimulation; empty, beads saturated with BSA; apo A-I, beads coated with apo A-I only; F1, beads coated with the F1 extra-membrane subunit
of bovine F1; and F1/apo A-I, beads coated with both protein preparations.
(A) T cell clones were activated with protein-coated beads in medium supplemented with human serum, and TNF secretion was measured
in the culture supernatant after 4 hr. The capacity of  clones G25, G115, and 73R9 to secrete significant amounts of TNF upon stimulation
was checked by using Daudi cells as target cells as well as PMA/ionomycin or PHA. The  clone A4.19 secretes saturating quantities of
TNF upon PMA/ionomycin or PHA stimulation (not shown).
(B) Stimulation was performed in the absence of exogenous serum (SFM), and purified HDL-derived apo A-I was added in some cultures
(black bars).
(C) Fresh PBL were activated with indicated beads for 4 hr in the presence Brefeldin A. Cells were then stained with antibodies to lymphocyte
subsets, fixed, and permeabilized, and TNF accumulation was analyzed after intracellular staining by flow cytometry. PMA/ionomycin
stimulation was used as a control for TNF-producing cells in the total population. Percentages indicating TNF-producing cells within analysis
quadrants and within each particular subset (between brackets) are shown.
is mimicked by exogenous apo A-I. Unlike ELISA experi- the contribution of apoA-I to TCRbinding. Nevertheless,
apo A-I could perform a chaperone-like function in thesements, SPR analysis allows detection of transient inter-
actions and reveals a possible binding site between interactions. In this regard, it will be interesting to deter-
mine whether other chaperones such as Hsp60 (Fisch etG115 TCR and apoA-I. This suggests that apo A-I some-
how stabilizes/increases TCR-F1 interaction by bridging al., 1990), which has been previously involved in V9V2
T cell-mediated recognition of Daudi cells and is knowndistinct binding sites on the TCR and the F1 chain.
Such an assumption is supported by the increased bind- to bind to scavenger receptors possibly related to apo
A-I receptors, could perform a similar role.ing of biotinylated soluble TCR to immobilized F1 com-
plexes containing apo A-I (Figure 7). The effect of serum In a recent work, Gober et al. (2003) found an in-
creased accumulation of ubiquitous endogenous IPP indeprivation on Daudi lysis by V9V2 T cells greatly
varies fromone clone to another, withG115 clones being tumors activating V9V2 T cell clones. Such accumula-
tion could account for continuous production of thesequite resistant to this deprivation. Thus, the G115-TCR
may not be the best receptor to use in order to assess antigens, so that cells remain activatory afterwashing. In
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contrast, washing antigen-presenting cells after pulsing
with exogenous IPP abrogates V9V2 T cell activation.
This work did not explore the possibility that secreted
IPP could be stably associated to components of the
cell surface or from the extracellular medium. The stable
modification of apo A-I or F1 by endogenous phos-
phoantigens is currently under investigation and beyond
the scope of the present work. Although blocking T cell
activation with anti-apo A-I or anti-F1 is (partially) re-
versed by exogenous addition of IPP, this reversal does
not exclude a simultaneous recognition of F1 with en-
dogenous phosphoantigenic ligands (Figure 4). How-
ever, this hypothesis may not fully explain the reactivity
of V9V2 T cells to phosphoantigens. Indeed, IPP or
other phosphoantigens can readily activate V9V2
T cells in the absence of any third party cells (Gober et
al., 2003; Lang et al., 1995; Morita et al., 1995). The
implication of F1 in IPP presentation would thus imply
Figure 6. Surface Plasmon Resonance Analysis of TCR Binding to F1 expression by  T cells. Despite this, all our attempts
Apo A-I and F1 to detect F1 on T cell effectors have failed so far (data
Soluble proteins were exposed to the sensorchip surface for 240 s not shown).
(association phase) followed by a 240 s flow running (dissociation Recognition by V9V2 T cells of F1, which is ex-
phase). Immobilized proteins were on sensorchips flow cell 2. Sen-
pressed on healthy tissues such as hepatocytes andsorgrams are representative of specific interactions (differential re-
endothelial cells, raises issues about the mechanismssponse) where nonspecific binding that occurred on flow cell 1 (with
preventing overt activation of V9V2 T cells by theseno protein immobilized) was deduced from binding that occurred
on flow cell 2. Results are expressed as resonance units (RU) as a self-structures under physiological conditions. As hy-
function of time in seconds. pothesized above, F1 may not be recognized per se
(A and B) Overlay sensorgrams for SPR analysis of soluble TCR in vivo but in association with phosphorylated ligands
protein binding to immobilized apo A-I. Amount of immobilized apo derived from microbial agents or stressed/transformed
A-I protein was 2260 RU on flow cell 2. Comparative sensorgrams
cells. Moreover, inhibitory NK receptors, which are fre-of soluble V9V2TCR and V8V3TCR (200 and 2000 nM) binding
quently found on V9V2 T cells and have been shownonto immobilized apoA-I (A). V9V2TCRwas injected at concentra-
to raise their activation threshold (Fisch et al., 1997;tions ranging from 125 nM to 2 M (B). The apparent kinetic con-
Halary et al., 1997), may prevent recognition of F1-bear-stants of the interaction were ka  8.8e3 
 6.08 e2 M1s1, kd  7.13
e3 
 6.76 e5 s1, and KD  8.1 e7 M. ing normal cells that express high levels of NK receptor
(C and D) Comparative SPR sensorgrams of soluble TCR binding ligands, such as HLA class I molecules.
to immobilized F1. Amount of immobilized F1 was 22440 RU on flow In conclusion, this study demonstrates cognate inter-
cell 2. Comparative sensorgrams of purified monomeric G115 TCR actions between a human  TCR and several defined
(V9V2, full line) and 73R9 TCR (V8V3, dotted line) binding to
structures, namely F1-ATPase and apo A-I. Togetherimmobilized F1 (C). Proteins were injected at a concentration of 2
with the high expression of LDL receptors and apoE inM.Monomeric G115 soluble TCR (V9V2) was injected at concen-
intraepithelial  lymphocytes (Fahrer et al., 2001), andtrations ranging from 0.5 to 4 M (D). The apparent kinetic constants
of the interaction were ka  1.68 e3 
 2.16 M1s1, kd  2.54 e3 
 studies documenting apoE binding to F1 (Mahley et al.,
2.9 e5 s1, and KD  1.51 e6M. 1989), these data open a new field of investigations
linking lipid metabolism and antitumor immunosurveil-
lance.
Figure 7. Soluble TCR Binding to Purified F1
ELISA plate microwells were coated with pu-
rified bovine ATP synthase (F1-F0) and satu-
rated with BSA. Soluble biotinylated mono-
meric G115 TCR (V9V2) was then added,
and TCR binding was measured by a stan-
dard streptavidin-alkaline phosphatase col-
orimetric test.
(A) Antibodies against  and  subunits of F1
(7H10 and 3D5, respectively) were added as
competitors at the indicated concentration
prior to the addition of soluble TCR.
(B) Some wells (white bars) were incubated
with an apo A-I preparation (hM5L, 50 g/ml)
andwashedprior to the addition of antibodies
and soluble TCR. All antibodies were added
at the concentration of 100 g/ml.
(C) To assess TCR binding specificity, G115
TCR was mixed with the indicated TCR anti-
bodies prior to addition of the mixture to F1-
F0-coated wells.
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Experimental Procedures expressed inEscherichia coli then refolded together by rapid dilution
in 1 liter of 1 M L-arginine, 0.1 M Tris-HCl, (pH 8.0), and 0.2 mM
reduced/0.2 mM oxidized glutathione. After dialysis against 10 mMTumor Cell Lines, T Cell Clones, and Cultures
Daudi, Raji, RPMI 8226, K562, Jurkat, Molt-4, U937, SK-NEP, G401, Tris-HCl (pH 8.0), concentration by cation exchange chromatogra-
phy at (pH 5.5), and purification by size exclusion chromatographyG402, and 786.0 were obtained from ATCC. Awells (EBV	 lympho-
blastoid B cell line) is from the International HistocompatibilityWork- at (pH 8.0), the refolded protein was biotinylated for 4 hr at 30C
with 6 g/ml BirA, and excess of free biotin was removed by dialysisshop (IHW#9090). C1R (HLA-AB-LCL) was obtained from Dr P.
Lebouteiller (Toulouse, France). All tumor cell lines were cultivated against 10 mM Tris-HCl (pH 8.0), 150 mM NaCl.
in RPMI 1640 medium supplemented with 10% fetal calf serum
(FCS) (Invitrogen) except for serum deprivation experiments. In this Protein Identification by Proteomic Analysis
case, cells were washed once in RPMI 1640, incubated for 1 hr at and Mass Spectrometry
37C in serum-free culture medium (hybridoma SFM, Invitrogen), Immunopurified material was analyzed by using one-dimensional
pelleted, and reincubated for at least 16 hr at 37C in SFM before electrophoresis and visualized by Coomassie blue staining. Protein
use. The G25 (V9V2) and 73R9 (V8V3) clones were obtained as bands were excised from the gel and subjected to several washing
described for G42 and G115 (Allison et al., 2001; Davodeau et al., steps, reduction alkylation reaction, in-gel trypsin digestion with
1993) by anti-V monoclonal antibody selection and subsequent modified trypsine (Promega, Madison, WI) at 25 ng/l in 50 mM
amplification with PHA and IL2 and cloning. NH4HCO3, and finally followed by peptide extraction. The peptides
purified with ZipTip C18 (Millipore) were mixed with equal volumes
Fluorescence Analysis and Antibodies (0.5 ml) of a saturated a-cyano-4-hydroxycinnamic acid in 50% ace-
Surface immunofluorescence stainings were performed in PBS con- tonitrile, 0.1% TFA onto the MALDI target and allowed to air dry.
taining 1% BSA and devoid of serum using FITC-conjugated goat Peptide mass fingerprinting was obtained by using a PE Biosystems
F(ab)2 anti-mouse Ig antibody (Caltag) as the second step reagent. MALDI-TOF mass spectrometer (Voyager DE STR, Foster City, CA,
Irrelevant isotype-matched control antibodieswere used as negative USA) on each protein band. Unknown proteins were identified with
controls. In apolipoprotein binding experiments, serum-deprived cells the database fitting program MS-Fit (Protein Prospector, http://
were incubated with serum or purified protein preparations in PBS prospector.ucsf.edu) and searching against all eukaryotic entries in
containing 1% BSA at room temperature 30 min prior to antibody Swiss Prot and NCBI nonredundant protein databases. We consid-
staining. 7H10 (anti--ATP synthase) and 3D5 (anti--ATP synthase) ered the identification positive when a minimum of four measured
are from Molecular Probes. 4H1 (anti-human apo A-I) (Collet et al., peptide masses were matched and provided at least around 20%
1997) was obtained fromDr Y. Marcel (Ottawa, Canada). TNF accu- sequence coverage. Mass accuracy of 10 ppm was obtained with
mulation in stimulated fresh PBL was analyzed after activation with internal calibration by using autodigestion peaks of trypsin (M	H	,
indicated latex beads for 4 hr in the presence brefeldin A. Cells 842.51, 2211.10, and 2283.18).
were then stained with antibodies to lymphocyte subsets, fixed, and
permeabilized, and TNF accumulation was analyzed after intracel- Chromium and Cytokine Release Assays
lular staining by flow cytometry. PMA/ionomycin stimulation was 2h-51Cr-release assays were performed in standard conditions ex-
used as a control for TNF-producing cells in the total population. cept for the use of serum-free conditions in some experiments: in
Anti-V2 (IMMU389), anti-NK (IM1847, anti CD158a), and anti-TCR sensitization experiments with apolipoprotein preparations, target
(BMA031) used for lymphocyte subset stainings are from Beck- tumor cells were serum deprived as described for FACS analysis,
man Coulter. loaded with 51Cr (100 Ci/106 cells, 1 hr, 37C), extensively washed
in RPMI, and resuspended in SFM medium. Effector T cells culti-
Generation of M5A12D10 Hybridoma vated in serum-containing medium were washed extensively in
and Antibody Purification RPMI, incubated for 2 hr in SFM at 37C, and resuspended in SFM
Balb/c mice were injected intraperitoneally four times at 2 week medium. Target cells (3000/well, in triplicates) were first incubated
intervals with 15 106 Daudi cells washed and resuspended in PBS. with apolipoprotein preparations or serum-containing medium for
Hybridoma were obtained by fusion of spleen cells with P3X63Ag8 30 min at room temperature in 96-well round-bottom microculture
myeloma cells and were selected on the basis of tumor cell staining. plates prior to the addition of effector cells. Cells were then pelleted
Subcloned hybridoma were subsequently amplified in SFM, and and incubated at 37C for 2 hr. Supernatants were recovered for
antibodies were purified on protein G affinity columns (Pharmacia), 51Cr-release measurement. Spontaneous release (in the absence of
neutralized, dialyzed against PBS, and concentrated (Harlow and effectors) was subtracted from experimental data and was in the
Lane, 1988). Finally, antibodies were tested for their ability to modu- 10%–30% range of maximum release (effector cells replaced by
late lysis of Daudi cells by  effectors, leading to the selection of same volume of 0.1 M HCl). Specific lysis was calculated as the
the M5A12D10 antibody (IgG1). percentage of maximum release. For antibody blocking experi-
ments, the percentage of inhibition was calculated according to the
formula: percentage of inhibition  [(percentage of specific lysisPurified Proteins
without antibody)(percentage of specific lysis with antibody)]/[per-The human and bovine ligands of M5A12D10 (hM5L and bM5L,
centage of lysis without antibody]  100.respectively) were isolated by affinity chromatography: human and
For cytokine release measurements, similar experiments werefetal calf serum diluted 1/20 in 3 M NaCl and 50 mM Tris (pH 7)
performed. Supernatants were harvested after 4 hr (TNF) or 20 hrwere passed through the column carrying the covalently attached
(IFN), and IFNwas titrated by a specific ELISA technique, whereasantibody. After washing (last wash was in 3 M NaCl, 10 mM Tris
TNF concentration was assessed by a biological assay based on[pH 7]), bound proteins were eluted with 100 mM glycine (pH 2.7).
WEHI cells viability.Isolation of apo A-I from high-density lipoproteins (HDL apo A-I) by
ion-exchange chromatography has been already described (Mez-
dour et al., 1987). Purity of apo A-I was checked by Western blot ELISA Assay for Soluble TCR Binding
analyses by using different antibodies directed against humanapoB, Purified mitochondrial ATP synthase (F1-F0, 10 g/ml) was coated
apo A-II, apo-C, and apo A-I. The apo A-I homogeneity was more on ELISA plates in 50 l of 0.1 M sodium carbonate buffer (pH 9.6),
than 99% (as measured by densitometry after SDS-PAGE and silver overnight at 4C. Wells were then saturated with BSA (10 mg/ml,
staining). A purified preparation of apo A-I was obtained from Sigma 2 hr, 22C) and washed (PBS, 0.1% tween 20). Soluble biotinylated
Co. Purified bovine heart mitochondrial ATP synthase (F1 and F1/ G115 TCR (V9V2) was added in 60 L (1 g/ml final concentration)
FO complexes) (Lutter et al., 1993)was obtained from John E.Walker for 30 min at 22C and wells were washed. Bound TCRwas revealed
(Cambridge, UK). by adding alkaline phosphatase-coupled streptavidin (Jackson Im-
muno-Research, 0.2 g/ml, 30 min, 22C) in 50 L of PBS, 0.1%
tween 20. After washing, N nitrophenyl dissodium was addedProduction of Soluble Recombinant TCR
The G115 (V9V2) (Allison et al., 2001) and 73R9 (V8V3) extracel- (1 g/ml) in 100 mL of alkaline phosphatase substrate buffer (8.7%
diethanolamine, 0.02% NaN3, and 0.1 g/L MgCl2). In competitionlular  and  chains (the latter carrying a short 3 biotin tag) were
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experiments, anti-F1 and anti-apo A-I antibodies were added at the tion of non-peptide antigens and Daudi cells analyzed by TCR gene
transfer. J. Immunol. 154, 998–1006.indicated concentration in 50L 15 min prior to the addition of solu-
ble TCR and were left in the medium. In order to study the effect Bukowski, J.F., Morita, C.T., and Brenner, M.B. (1999). Human
of apo A-I on TCR binding to F1, hM5L (100 g/ml) was added on gamma delta T cells recognize alkylamines derived from microbes,
F1-F0-coated, BSA-saturated wells for 1 hr in 0.1M carbonate buffer edible plants, and tea: implications for innate immunity. Immunity
(pH 8.3) at 22C andwells were then washed. To study the specificity 11, 57–65.
of TCR binding to immobilized F1-F0, anti-TCR antibodies were
Chambenoit, O., Hamon, Y., Marguet, D., Rigneault, H., Rosseneu,
mixed with soluble TCR, and the mixture was added after 30 min
M., and Chimini, G. (2001). Specific docking of apolipoprotein A-I
to F1-coated, BSA-saturated wells. Optical density was measured
at the cell surface requires a functional ABCA1 transporter. J. Biol.
at 405 nm with a 595 nm reference. Results are expressed as the
Chem. 276, 9955–9960.
mean optical density of triplicate wells after blank subtraction (wells
Collet, X., Marcel, Y.L., Tremblay, N., Lazure, C., Milne, R.W., Perret,without F1). Plate reading was performed before an optical density
B., and Weech, P.K. (1997). Evolution of mammalian apolipoproteinof 0.1 OD405 unit was reached in blank wells.
A-I and conservation of antigenicity: correlation with primary and
secondary structure. J. Lipid Res. 38, 634–644.Immobilization of Proteins on Latex Beads
Constant, P., Davodeau, F., Peyrat, M.A., Poquet, Y., Puzo, G.,107 sulfate latex beads (Interfacial Dynamics Corp., Portland, OR)
Bonneville, M., and Fournie, J.J. (1994). Stimulation of humanwere washed in PBS and incubated with apolipoproteins (100
gamma delta T cells by nonpeptidic mycobacterial ligands. Scienceg/ml), F1-ATPase (0.4 mg/ml), or a mixture of both under constant
264, 267–270.agitation at room temperature for 16 hr. Beads were then washed,
saturated for 3 hr in PBS containing 1% BSA, and washed exten- Crowley, M.P., Fahrer, A.M., Baumgarth, N., Hampl, J., Gutgemann,
sively in PBS before use. Control “empty” beads were similarly I., Teyton, L., and Chien, Y. (2000). A population of murine gamma-
saturated with BSA. In stimulation experiments, beads were mixed delta T cells that recognize an inducible MHC class Ib molecule.
with cells at a 1:1 ratio. Science 287, 314–316.
Das, B., Mondragon, M.O., Sadeghian, M., Hatcher, V.B., and Norin,
SPR (Biacore) Analysis A.J. (1994). A novel ligand in lymphocyte-mediated cytotoxicity: ex-
Apo A-I and F1 were immobilized by amine linkage on CM5 chips pression of the beta subunit of H	 transporting ATP synthase on
(Biacore AB) after NHS-EDC activation. Binding was analyzed in a the surface of tumor cell lines. J. Exp. Med. 180, 273–281.
Biacore 3000 apparatus. Soluble ligands were injected at a flow rate Davis, M.M., Boniface, J.J., Reich, Z., Lyons, D., Hampl, J., Arden,
of 20 l/min, exposed to the surface for 240 s (association phase), B., and Chien, Y. (1998). Ligand recognition by alpha beta T cell
followed by a 240 s flow running during which the dissociation receptors. Annu. Rev. Immunol. 16, 523–544.
occurred. Between injections, in order to recover the prebinding
Davodeau, F., Peyrat, M.A., Houde, I., Hallet, M.M., De Libero, G.,baseline, the sensorchip surfacewas regenerated by a 5L injection
Vie, H., and Bonneville, M. (1993). Surface expression of two distinctof 0.01% SDS (15 s of contact time).
functional antigen receptors on human gammadelta T cells. Science
260, 1800–1802.
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